AKT1 and gastric cancer: In this context, the treatment of a murine model of gastric cancer harboring RhoA-Y42 mutation, with anti-CD36 mAb or a selective PI3Kβ small molecule inhibitor (GSK2636771), inhibits AKT phosphorylation and strongly decreases the number of TA-Tregs by reducing the total FFA production in the TME [231].